Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overloadJadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral film-coated tablet for iron chelationJadenu, taken with or without food, simplifies daily treatment administration for patients with chronic iron overloadChronic iron overload is a serious condition that can affect people with sickle cell disease, thalassemia and myelodysplastic syndromes